Global Counterfeit Drug Detection Device Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Modality (Portable Devices, Hand-Held Devices, Bench-Top Devices), By Product Type (RFID Analyzer, Scanning And Imaging Systems, Chromatographs, Spectrometers, Spectroscopes), By End User (Pharmaceutical Companies, Drug Testing Laboratories, Research Organizations), And By Geography- Forecasts From 2022 To 2027

  • Published : Sep 2022
  • Report Code : KSI061613498
  • Pages : 114

The global counterfeit drug detection device market is estimated to grow at a CAGR of 6.62% to reach a market size of US$1,437.771 million in 2027 from US$917.736 million in 2020.

The growing advancements in counterfeit drug detection technology are propelling the market demand in the forecast period. The growing concerns regarding counterfeit drug intake giving rise to an increasing number of deaths worldwide are further fueling the market demand in the forecast period. Counterfeit drugs are posing a challenge to public health at the global level. The extent of this problem is quite difficult to quantify. According to the WHO, counterfeit drugs account for approximately 10% of the global market; in some countries, counterfeit drugs account for more than 30%. In certain drug markets where there are stringent regulatory systems, including Australia, Canada, and many EU countries, these fake drugs represent less than 1% of the total market value. With growing internet penetration, counterfeiters get an opportunity to sales of these drugs at the international level. As per the WHO estimates, around 50% of the drugs sold are found on various illegal websites with hidden physical addresses.  The global prevalence of diseases, combined with the prevalence of an unaware population regarding counterfeit drugs in low- and middle-income countries, results in massive illnesses and massive losses for pharmaceutical companies.

Geographically, North America is projected to hold a significant market share, followed by the European region due to the presence of stringent regulations to prevent the entry of fake medicines. The Asia Pacific region, on the other hand, is estimated to be the fastest-growing region with the presence of market players manufacturing drug testing devices in this region.

 Growing technological advancements are driving the growth of the global counterfeit drug detection device market in the forecast period.

With globalization, it has been realized that this has also increased the problems related to the prevention of the marketing of false medicines. Hence, technological advancements are taking place to overcome this issue. Funding was provided to scientists in the European Union for the development of a device for the detection of fake drugs at the borders and airports. The CONPHIRMER project, the Counterfeit Pharmaceuticals Interception using radiofrequency methods in real-time, utilized quadrupole resonance (QR) spectroscopy for the development of the prototype. This technology operates based on the utilization of radio frequency (RF) for the exciting and detecting of specific atoms like active pharmaceutical ingredients, which are present in real and genuine drugs. The researchers created a database of certain counterfeited drugs along with their QR fingerprints based on APIs. The researchers further compared the QR responses of different medicines with different APIs by utilizing multiple RF pulse sequences. The researchers were able to develop a better second-generation detection device based on the first-generation techniques. The project partners demonstrated a laboratory-based proof of concept successfully. The final portable device prototype consists of a hand-held antenna for capturing QR signals from the drugs. The device is well-suited for the examination of postal packages due to its non-invasive and non-destructive properties. It is available in a portable format and can be easily introduced into the postal sorting facility, thereby allowing the differentiation between genuine drugs and fake drugs. Thus, this technology will help control counterfeit drug trafficking, and protect the health and well-being of the citizens of the European Union nations.

The presence of companies with sophisticated fake drug detection devices is driving market growth in the forecast period.

Thermo Fischer Scientific portable XRF Analyzer, NIR, and Raman Spectrometer for the analysis of pharma drugs and manufacturing are capable of on-site identification and quantification of pharmaceutical drug commodities. This further achieves maximum quality coverage in addition to minimizing time-consuming laboratory sampling tests. With the company’s handheld NIT analyzer and Raman spectrometers, the pharma and biotech organizations are capable of obtaining fast and accurate analysis results, in addition to raw material verification. This is achieved within 30 seconds, hence, proving to combat the spread of false medicine. The devices are designed as per current good manufacturing practices and 21 CFR Part 11. The TruScan Raman and microPHAZIR RX NIR analyzer are capable of helping achieve high-quality verification and analysis.

With drug formulations having a unique fingerprint of active and inactive ingredients, these help in the identification of the efficacy and brand of every drug. Incorrect formulations that contain foreign or substitute ingredients are capable of risking a patient’s well-being. Additionally, with the distribution, and the formation of incorrect and counterfeit drug formulations, the manufacturer’s reputation is at risk.  To protect their business interests, drug manufacturers ensure that the right formulation is been distributed to their customers. Hence, this will further protect the brand. For this, manufacturers are adopting non-destructive fingerprinting techniques for their drug formulations. The drug formulation can be quickly scanned, at any stage, by measuring its crystalline structure. Olympus Corporation TERRA™ II XRD analyzer provides portable quantitative mineralogy. The battery life is for up to six hours, with a rugged and weatherproof case, the device is designed for fast in-field analysis of major and minor components. The other product, namely the BTX™ III XRD Analyzer, provides reliable quantitative mineralogy of major and minor components. The product is in the form of a bench-top design. It also contains powerful software with an X-ray detector for increased speed and sensitivity.

Spectral Engines NIRONE® Scanner provides a turnkey material sensing solution for material sensing applications. This scanner includes the world’s smartest material scanner, which is equipped with state-of-the-art NIR technology, an easy-t-use mobile app, cloud connectivity, and advanced algorithms.

The important part of the scanner is an intelligent cloud for fast data collection and analysis. The scanner includes NIRONE Scanners, NIRONE Scanner Mobile App, NIRONE Scanner Web App, and advanced cloud computing algorithms for material analysis. This award-winning product is a perfect solution for the detection of fake medicines.

Recent Development and expansions

A novel AI-enhanced image inspection solution was released, by Stratio, Inc., in December 2021. At border inspections, the new Stratio, Inc. technology can quickly identify design infringements on questionable merchandise. The AI Convergence for Illegal Counterfeit Inspection System project was created with assistance from South Korea's National IT Industry Promotion Agency (NIPA) to play a crucial role in assisting the Korean government in identifying cases of design infringement at border checkpoints.

COVID-19 Impact on Counterfeit Drug Detection Device Market

The market for counterfeit medication detection devices benefited from COVID-19. New medical items, gadgets, and medications were widely introduced to the market during this pandemic timeframe. It suggests that counterfeit drugs and medications became available later. This increased demand from pharmacies, healthcare organizations, and end users for counterfeit medicine detection tools.

Counterfeit Drug Detection Device Market Scope:

 

Report Metric Details
 Market Size Value in 2020  US$917.736 million
 Market Size Value in 2027  US$1,437.771 million
 Growth Rate  CAGR of 6.62% from 2020 to 2027
 Base Year  2020
 Forecast Period  2022 – 2027
 Forecast Unit (Value)  USD Million
 Segments Covered  Modality, Product Type, End User, And Geography
 Regions Covered  North America, South America, Europe, Middle East and Africa, Asia Pacific
 Companies Covered Spectris, Spectral Engines Oy, Consumer Physics, Olympus Corporation, Stratio, Inc., Rigaku Corporation, Thermo Fisher Scientific Inc.
 Customization Scope  Free report customization with purchase

 

Segmentation:

  • By Modality
    • Portable Devices
    • Hand-Held Devices
    • Bench-Top Devices
  • By Product Type
    • RFID Analyzer
    • Scanning and Imaging Systems
    • Chromatographs
    • Spectrometers
    • Spectroscopes
  • By End User
    • Pharmaceutical Companies
    • Drug Testing Laboratories
    • Research Organizations
  • By Geography
    • North America
      • USA
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • UK
      • Germany
      • France
      • Others
    • Middle East and Africa
      • UAE
      • Israel
      • Saudi Arabia
      • Others
    • Asia Pacific
      • Japan
      • China
      • India
      • Australia
      • South Korea
      • Thailand
      • Indonesia
      • Taiwan
      • Others

Frequently Asked Questions (FAQs)

The counterfeit drug detection device market is estimated to grow at a CAGR of 6.62% during the forecast period.
The growing advancements in counterfeit drug detection technology are propelling the market demand in the forecast period.
The global counterfeit drug detection device market is estimated to reach a market size of US$1,437.771 million by 2027.
Geographically, North America is projected to hold a significant share of the counterfeit drug detection device market due to the presence of stringent regulations to prevent the entry of fake medicines.
Counterfeit Drug Detection Device Market was valued at US$917.736 million in 2020.
1. Introduction
1.1. Market Overview
1.2. COVID-19 Scenario
1.3. Market Definition
1.4. Market Segmentation

2. Research Methodology  
2.1. Research Data
2.2. Assumptions

3. Executive Summary
3.1. Research Highlights

4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. Global Counterfeit Drug Detection Device Market Analysis, by Modality
5.1.  Introduction
5.2.  Portable Devices
5.3.  Hand-Held Devices
5.4.  Bench-Top Devices

6. Global Counterfeit Drug Detection Device Market Analysis, By Product Type
6.1. Introduction
6.2.  RFID Analyzer
6.3.  Scanning and Imaging Systems
6.4.  Chromatographs
6.5.  Spectrometers
6.6.  Spectroscopes

7. Global Counterfeit Drug Detection Device Market Analysis, By End User
7.1. Introduction
7.2.  Pharmaceutical Companies
7.3.  Drug Testing Laboratories
7.4.  Research Organizations

8. Global Counterfeit Drug Detection Device Market Analysis, by Geography
8.1. Introduction
8.2.  North America
8.2.1. United States
8.2.2.  Canada
8.2.3.  Mexico
8.3.  South America
8.3.1. Brazil
8.3.2.  Argentina
8.3.3.  Others
8.4.  Europe
8.4.1.  UK
8.4.2.  Germany
8.4.3.  France
8.4.4.  Others
8.5.  Middle East and Africa
8.5.1. United Arab Emirates
8.5.2.  Israel
8.5.3.  Saudi Arabia
8.5.4.  Others
8.6.  Asia Pacific
8.6.1.  Japan
8.6.2.  China
8.6.3.  India
8.6.4.  Australia
8.6.5. South Korea
8.6.6. Indonesia
8.6.7. Thailand
8.6.8. Taiwan
8.6.9.  Others

9.  Competitive Environment and Analysis
9.1. Major Players and Strategy Analysis
9.2.  Emerging Players and Market Lucrativeness
9.3.  Mergers, Acquisitions, Agreements, and Collaborations
9.4.  Vendor Competitiveness Matrix

10.  Company Profiles 
10.1. Spectris
10.2.  Spectral Engines Oy
10.3.  Consumer Physics
10.4.  Olympus Corporation
10.5.  Stratio, Inc
10.6.  Rigaku Corporation
10.7.  Thermo Fisher Scientific Inc

Spectris

Spectral Engines Oy

Consumer Physics

Olympus Corporation

Stratio, Inc.

Rigaku Corporation

Thermo Fisher Scientific Inc.